Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T11911
|
||||
Former ID |
TTDI03307
|
||||
Target Name |
KCa2.1
|
||||
Gene Name |
KCNN1
|
||||
Synonyms |
KCNN1
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Myeloneuropathy [ICD10: G04.1] | ||||
UniProt ID | |||||
Sequence |
MNSHSYNGSVGRPLGSGPGALGRDPPDPEAGHPPQPPHSPGLQVVVAKSEPARPSPGSPR
GQPQDQDDDEDDEEDEAGRQRASGKPSNVGHRLGHRRALFEKRKRLSDYALIFGMFGIVV MVTETELSWGVYTKESLYSFALKCLISLSTAILLGLVVLYHAREIQLFMVDNGADDWRIA MTCERVFLISLELAVCAIHPVPGHYRFTWTARLAFTYAPSVAEADVDVLLSIPMFLRLYL LGRVMLLHSKIFTDASSRSIGALNKITFNTRFVMKTLMTICPGTVLLVFSISSWIIAAWT VRVCERYHDKQEVTSNFLGAMWLISITFLSIGYGDMVPHTYCGKGVCLLTGIMGAGCTAL VVAVVARKLELTKAEKHVHNFMMDTQLTKRVKNAAANVLRETWLIYKHTRLVKKPDQARV RKHQRKFLQAIHQAQKLRSVKIEQGKLNDQANTLTDLAKTQTVMYDLVSELHAQHEELEA RLATLESRLDALGASLQALPGLIAQAIRPPPPPLPPRPGPGPQDQAARSSPCRWTPVAPS DCG |
||||
Drugs and Mode of Action | |||||
Drug(s) | dequalinium | Drug Info | Clinical trial | Myeloneuropathy | [1] |
Blocker (channel blocker) | apamin | Drug Info | [2] | ||
dequalinium | Drug Info | [2] | |||
tetraethylammonium | Drug Info | [3] | |||
UCL1684 | Drug Info | [3] | |||
UCL1848 | Drug Info | [4] | |||
Activator | EBIO | Drug Info | [3] | ||
References | |||||
REF 1 | Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology. 2001 May;40(6):772-83. | ||||
REF 2 | Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9. | ||||
REF 3 | Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. | ||||
REF 4 | The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines. Br J Pharmacol. 2000 Feb;129(4):627-30. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.